^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Myeloproliferative Neoplasm

    1d
    A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms (clinicaltrials.gov)
    P1, N=220, Recruiting, Janssen Research & Development, LLC | Trial completion date: Dec 2027 --> Apr 2028
    Trial completion date • First-in-human • CALR
    |
    CALR (Calreticulin)
    |
    Jakafi (ruxolitinib) • Ojjaara (momelotinib)
    4d
    A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms (clinicaltrials.gov)
    P1, N=100, Not yet recruiting, Prelude Therapeutics
    New P1 trial • First-in-human
    |
    JAK2 (Janus kinase 2)
    4d
    Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia (clinicaltrials.gov)
    P2, N=35, Not yet recruiting, Jonsson Comprehensive Cancer Center
    New P2 trial
    |
    Besremi (ropeginterferon alfa-2b-njft)
    4d
    Clinical and hematological profile of patients with philadelphia-negative myeloproliferative neoplasms: First report from the Ecuadorian registry. (PubMed, Hematol Transfus Cell Ther)
    These results reveal a relatively homogeneous epidemiological profile across the Latin American region and underscore the need for more multicenter studies to better characterize pH- MPNs in Ecuador and the region, to optimize diagnostic and treatment strategies.
    Journal
    |
    JAK2 (Janus kinase 2)
    |
    hydroxyurea
    4d
    OSU-23442: Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia (clinicaltrials.gov)
    P1/2, N=52, Recruiting, Uma Borate | Trial completion date: Dec 2026 --> Oct 2028 | Trial primary completion date: Dec 2025 --> Oct 2027
    Trial completion date • Trial primary completion date
    |
    SF3B1 (Splicing Factor 3b Subunit 1)
    |
    SF3B1 mutation
    |
    azacitidine • Niktimvo (axatilimab-csfr)
    5d
    NCI-2019-03188: Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS) (clinicaltrials.gov)
    P2, N=120, Recruiting, Fred Hutchinson Cancer Center | Trial completion date: Dec 2028 --> Dec 2029 | Trial primary completion date: Dec 2026 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    cyclophosphamide • sirolimus • fludarabine IV • thiotepa • busulfan • cyclosporin A microemulsion • methotrexate IV
    6d
    Large PPM Lead-Associated Thrombus in a JAK2-Positive Patient. (PubMed, JACC Case Rep)
    Large intracardiac CIED-related thrombi remain clinically significant but poorly studied. Anticoagulation is the mainstay of treatment, however decisions are highly individualized.
    Journal
    |
    JAK2 (Janus kinase 2)
    6d
    Predominant Merkel Cell Polyomavirus DNA Detection in Essential Thrombocythemia within Myeloproliferative Neoplasms. (PubMed, Cancer Res Commun)
    Interestingly, MCPyV positivity was significantly correlated with female sex but not with age or specific MPN genetic mutations, except for myeloproliferative leukemia virus oncogene (MPL) mutations. These findings suggest a potential association between MCPyV and MPNs, particularly ET, and support further investigation into the role of human polyomavirus in megakaryocytic lineage biology.
    Journal
    |
    MPL (MPL Proto-Oncogene, Thrombopoietin Receptor)
    6d
    Ph-chromosome-negative myeloproliferative neoplasms: clonal dynamics are the name of the game. (PubMed, Blood Rev)
    Recent advances like single-cell DNA sequencing (scDNA-seq) provide data on the clonal dynamics of Ph-chromosome-negative MPNs. We comprehensively review genomic profiles, clonal evolution and risk of leukaemia transformation, emphasizing the importance of clonal architecture.
    Review • Journal
    |
    JAK2 (Janus kinase 2) • CALR (Calreticulin)
    7d
    The Intricate Dance Between Inflammation and Myeloproliferative Neoplasms: From Origins to Outcomes. (PubMed, Curr Hematol Malig Rep)
    Inflammation is inseparable from MPN biology and represents both a driver and a therapeutic target. Reframing MPN as a disorder of maladaptive immune and stromal interactions highlights opportunities to restore balance within this ecosystem and potentially alter disease course.
    Review • Journal
    |
    JAK2 (Janus kinase 2)
    7d
    An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms (clinicaltrials.gov)
    P1/2, N=27, Recruiting, University of California, Irvine | Trial primary completion date: Jul 2025 --> Nov 2026
    Trial primary completion date